Roche's top three best sellers accounting for 43% of all sales are expected to lose exclusivity this year.
Despite this ominous patent cliff, Roche remains a great defensive pick.
This article extrapolates a worst-case scenario based on declines from already available biosimilars and explains why Roche can overcome.
Additionally, Roche has been very responsible with its capital, spending almost nothing on buybacks and investing in R&D and M&A.
Roche (OTCQX:RHHBY) is hitting an enormous patent cliff this year that will see its top three best selling drugs lose exclusivity. In fact, those three drugs are in first, third, and fourth place